Evidence map›Paper›PMID 40561047›Full record

ArticleHuman vaccines & immunotherapeutics2025

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.

Annefleur C Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes and 1 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annefleur C LangedijkMedical Affairs, Pfizer B.V., Capelle aan den IJssel, the Netherlands.
Floris van den DungenHTA & Access, Pfizer B.V., Capelle aan den IJssel, the Netherlands.
Lisette HarteveldDepartment of Pediatrics and Vaccine, Infection and Immunology, Spaarne Gasthuis Hospital, Haarlem, the Netherlands.
Jennie van den BoerMidwives Amsterdam Zuid, Amsterdam, the Netherlands.
Lucy SmitYouth Health Care Center, Jeugdgezondheidszorg Kennemerland, Velserbroek, the Netherlands.
Ahuva AverinEvidence & Strategy, Advisory, Avalere Health, Boston, MA, USA.
Erin QuinnEvidence & Strategy, Advisory, Avalere Health, Boston, MA, USA.
Mark AtwoodEvidence & Strategy, Advisory, Avalere Health, Boston, MA, USA.
Amy LawHTA, Value & Evidence, Pfizer Inc., New York, NY, USA.
Diana MendesHTA, Value & Evidence, Pfizer Ltd., Tadworth, UK.
Marlies van HoutenDepartment of Pediatrics and Vaccine, Infection and Immunology, Spaarne Gasthuis Hospital, Haarlem, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch data, include rates of disease, case-fatality, general mortality; disutility; and costs of interventions, medical care, treatment-related travel, and disease-associated work loss. Uptake of interventions assumed 70%; effectiveness was based on a published study using Phase III trial data. Analyses were conducted from the societal perspective using 2023 EUR; annual discount rates were 3% for costs and 1.5% for quality-adjusted life-years (QALYs). With no intervention, there were 10,482 RSV-LRTD cases with total associated costs of € 17.4M. Nirsevimab alone prevented 4,905 cases, yielding 100 QALYs; total costs increased by € 59.3M due to high intervention costs and cost-effectiveness was € 592,404/QALY (vs. no intervention). RSVpreF with complementary nirsevimab for infants prevented 4,723 cases, yielding 108 QALYs; total costs increased by € 35.5M and cost-effectiveness was € 329,187/QALY (vs. no intervention). Maternal RSVpreF with complementary nirsevimab was more cost-effective than nirsevimab alone.

Indexed as

Antibodies, Monoclonal, HumanizedCost-Benefit AnalysisImmunizationRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccinationFemaleHumansInfantInfant, NewbornMaleNetherlandsAntibodies, Monoclonal, HumanizedRespiratory Syncytial Virus Vaccinescost-effectiveness analysisinfantsmaternally acquired immunitymonoclonal antibodypassive immunizationRespiratory syncytial virusthe Netherlands

Identifiers

PMID40561047
PMCPMC12934181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.